{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"description":"A DLT was defined as any Grade 3 or greater study intervention-related AE that was clinically significant.","groups":[{"description":"Participants received CAEL-101 500 mg/m\\^2 administered weekly as an IV infusion the first 4 weeks (DLT observation period), and thereafter received CAEL-101 at the RP3D (1000 mg/m\\^2) every other week until the end of study, in combination with the SoC CyBorD.","id":"OG000","title":"Part A: CAEL-101 500 mg/m^2 Combined With SoC CyBorD"},{"description":"Participants received CAEL-101 750 mg/m\\^2 administered weekly as an IV infusion the first 4 weeks (DLT observation period), and thereafter received CAEL-101 at the RP3D (1000 mg/m\\^2) every other week until the end of study, in combination with the SoC CyBorD chemotherapy.","id":"OG001","title":"Part A: CAEL-101 750 mg/m^2 Combined With SoC CyBorD"},{"description":"Participants received CAEL-101 1000 mg/m\\^2 administered weekly as an IV infusion the first 4 weeks, and then every other week until the end of study, in combination with the SoC CyBorD chemotherapy.","id":"OG002","title":"Part A: CAEL-101 1000 mg/m^2 Combined With SoC CyBorD"},{"description":"Participants received CAEL-101 at the RP3D (1000 mg/m\\^2) administered weekly as an IV infusion for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy and daratumumab.","id":"OG003","title":"Part B: CAEL-101 Combined With SoC CyBorD and Daratumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Set included all participants who were treated with at least 1 dose of CAEL-101.","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Number of Participants With Dose-limiting Toxicity (DLT) During the First 4 Weeks of Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}